Drug discovery is moving away from the single target-based approach towards harnessing the potential of polypharmacological agents that modulate the activity of multiple nodes in the complex networks of deregulations underlying disease phenotypes. Computational network pharmacology methods that use systems-level drug-response phenotypes, such as those originating from genome-wide transcriptomic profiles, have proved particularly effective for elucidating the mechanisms of action of multitargeted compounds. Here, we show, via the case study of the natural product pinosylvin, how the combination of two complementary network-based methods can provide novel, unexpected mechanistic insights. This case study also illustrates that elucidating the mechanism of action of multitargeted natural products through transcriptional response-based approaches is a challenging endeavor, often requiring multiple computational-experimental iterations. Corresponding author: Kibble, M. (milla.kibble@helsinki.fi) 1359-6446/ß
Introduction
Over the past few decades, drug discovery has adopted a target-based approach, searching for compounds that target a specific disease-causing gene product [1] . Perhaps the most successful example of the target-based approach was the discovery of imatinib, a BCR-ABL tyrosine kinase inhibitor (TKI), for the treatment of several cancers, including Philadelphia chromosome-positive chronic myeloid leukemia (CML) [2] . However, recently, the paradigm of searching for highly Reviews 
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Tero Aittokallio received his PhD in applied mathematics from the University of Turku in 2001. He did his postdoctoral training in the Systems Biology Lab at the Institut Pasteur (2006) (2007) , where he focused on network biology applications using high-throughput experimental assays. Dr Aittokallio then launched his independent career as a principal investigator in the Turku Biomathematics Research Group in 2007, and received a 5-year appointment as an Academy of Finland Research Fellow (2007) (2008) (2009) (2010) (2011) (2012) . In 2011, he started as EMBL Group Leader at FIMM, where his research group is developing systems medicine solutions for biomedical problems, with a particular interest in personalized medicine. selective ligands has been questioned, because of high late-stage clinical attrition rates, which can be largely attributed to lack of clinical efficacy and safety [3] [4] [5] [6] . With the recognition that many approved drugs are in fact multitargeted, an alternative systems biology approach to drug discovery is increasing in popularity. The so-called 'network pharmacology paradigm' [7] (see Glossary) makes use of systems-level disease models, aiming at finding compounds (or combinations thereof) that can modulate the activity of multiple nodes in the complex network of impaired mechanisms and deregulated interactions underlying a disease phenotype (i.e., the 'disease network'), either by targeting several pathways or by working synergistically, potentially with fewer adverse effects [8, 9] .
Therefore, an essential part of the modern drug discovery process is the elucidation of the multiple target mechanisms of compounds to better understand their phenotypic effects, both therapeutic and adverse. Here, computational methods offer great potential to provide initial hypotheses for in vitro and in vivo target validation studies. In particular, a class of computational drug-discovery methods that use comprehensive drug response phenotypes, such as those originating from genome-wide transcriptomic profiles, has proved particularly effective in elucidating compound mechanisms of action (MoA). These methods were initiated about a decade ago, with the advent of the Connectivity Map (CMap) data resource [10] . New types of drug response profile are continuously being produced, for example, from community efforts such as the Library of Integrated Network-based Cellular Signatures project (LINCS, http://www. lincsproject.org/), which aims to provide a comprehensive reference data resource of cellular response signatures to a range of small-molecule and genetic perturbations.
Here, we describe how the combination of two complementary computational network pharmacology methods, namely Mode of Action by Network Analysis (MANTRA) [11] and Group Factor Analysis (GFA) [12] , can provide novel, unexpected MoA predictions. As a specific case, we illustrate the operation of these methods in the context of multitargeted natural products. Although less popular during the era of target-based drug discovery, natural products still make a substantial contribution to current new drugs [13] [14] [15] [16] . Recent reviews have highlighted the largely untapped potential of network pharmacology approaches in natural product research [17] [18] [19] [20] ; we chose as our case study a relatively little-researched natural polyphenol, pinosylvin (3,5dihydroxy-trans-stilbene). Pinosylvin has been shown to have antiproliferative and proapoptotic efficacy on prostate cancer cells in vitro and in vivo [21] , but its MoA has so far been poorly understood. In this study, we show that the true value of the data-driven network-based methods is their potential to lead to unbiased hypotheses that might not otherwise have been conceived and, hence, to truly novel and even surprising findings.
Transcriptional response networks to elucidate drug MoA
We illustrate the operation of the computational network pharmacology methods using genome-wide gene expression response profiles as their input. The main public resource for such data is the CMap resource, which comprises genome-wide transcriptional responses of various human cell lines to more than 1000 bioactive small molecules ( Table 1 ). Given that our example compound pinosylvin is not included in this resource, we produced a response profile for pinosylvin in house (Box 1). Since the advent of the CMap resource, researchers have successfully discovered cellular targets of compounds and identified candidates for drug repositioning by searching for commonalities in the phenotypic responses using the simple idea that, if two drugs elicit similar transcriptional responses, then they could share a common MoA (hence, potentially a therapeutic application) even if directly acting on different intracellular targets. The original CMap tool compares transcriptional response profiles using a method similar to Gene Set Enrichment Analysis (GSEA) [22] , based on the Kolmogorov-Smirnov statistic. Furthermore, computational researchers have provided an abundance of methods for measuring the similarity between genome-wide transcriptional responses.
For an overview of all developments over the past 10 years, many of which represent different variations of the original GSEA method, we refer the reader to the previous reviews by Iorio et al. [23] and by Qu et al. [24] of in silico approaches using in vivo and in vitro transcriptomic drug response profiles, and we comment on the new methods that have been published subsequent to the aforementioned reviews. A key recent development is the addition of new types of information source to the network-based methods. For example, Jahchan et al. [25] used additional information on the enriched pathways of the molecules that are most similar to the compound of interest in terms of transcriptional response, Laenen et al. [26] incorporated a functional protein association network into their computational model and Wu et al. [27] incorporated an adverse effect profile based on differential expression of essential genes. Quan et al. [28] used an approach to transcriptional response similarity assessment that utilizes the REVIEWS Drug Discovery Today Volume 21, Number 7 July 2016 GLOSSARY Batch effect the similarity of gene expression or other molecular profiles observed for unrelated stimuli in cells grown or processed simultaneously. Drug network a network in which drugs are represented by nodes and nodes are connected if two drugs are similar in a predefined manner (here, in terms of their transcriptional response). Drug repositioning the discovery of new uses for approved drugs, which have well-known safety and pharmacokinetic profiles [23] . Gene expression profile a list of probe set identifiers, ranked according to differential gene expression in a particular cellular context, with the most upregulated probe sets at the top of the list. Mechanism of action (MoA) the set of cellular targets or other mechanisms of a compound that produce its pharmacological effect in a given cellular context. Network biology systems-level modeling of biological processes, pathways, and molecular interactions, rather than focusing on individual players only. Network pharmacology conceptualization of the fact that, in certain cases, to have an effect, drugs must target multiple pathways in a disease network and/or work synergistically with other drugs.
Synergy the joint action of drugs that when used together increase each other's effectiveness. See [80] for a discussion of the challenges of modeling synergistic interactions.
idea of drug-induced transcriptional modules [29] . Also, some novel probabilistic methodologies are beginning to emerge [30, 31] as well as a new combined unsupervised and supervised approach [32] . Finally, Napolitano et al. [33] conceived Drug-Set Enrichment Analysis to investigate commonalities in the MoA of a set of pharmacologically diverse compounds that are nevertheless able to induce a common phenotype. An application of a similar method to cystic-fibrosis phenotype correctors is presented in [34] . Most recently, Woo et al. [35] introduced a method, called DeMAND, for predicting the MoA of a compound using tissuespecific regulatory networks and Cmap-type transcriptional profiles in response to in vitro or in vivo compound perturbations. Specifically, they combined genome-wide gene expression profiles from human lymphoma cells with a lymphoma-specific gene interaction network, and used the Kullback-Leibler divergence [36] to establish compound-mediated dysregulation of given gene nodes in the network. Although the authors were able to experimentally prove their MoA predictions, one limitation of this approach is the requirement for high-quality, context-specific gene regulatory networks. However, as the authors comment, these might well be temporary limitations, because many groups are working on reliable methods to produce such networks for various cancer types. Once available on a large scale, such tissue-specific models have the potential to lead to the identification of more effective and safe therapeutic targets [37] .
Here, we focus in more detail on two recent complementary network-based methods, namely MANTRA [11] , and GFA [12] , for elucidation of compound MoA. In brief, the MANTRA method is based on the GSEA method to measure the similarity between transcriptional response profiles; it uses solely the transcriptional response data, which are aggregated across the different cancer cell lines to dilute cell line-specific effects on transcription as well as batch effects and other confounding factors, such as multiple drug Drug Discovery Today Volume 21, Number 7 July 2016 REVIEWS To link targets of closest neighbors of pinosylvin to their underlying pathways dosages. By contrast, the GFA method is a probabilistic model that considers cell line-specific transcriptional responses and can also incorporate structural information about the compounds. We hypothesized that the use of such complementary methods would lead to a more comprehensive elucidation of MoA of multitargeted compounds. We begin by describing the two methods and their outputs using as an example case the natural product pinosylvin. Finally, we demonstrate the added value of using more than one method in providing valuable insights that single methods alone could not predict.
Operation of the MANTRA method
As detailed in Box 2, the MANTRA method [11] produces a ranked list of CMap compounds based on the similarity of their gene expression profiles to that of the input compound, here pinosylvin ( Table 2 ). The underlying idea of this network-based approach is to discover the MoA of the compound of interest via neighboring compounds that produce a similar transcriptional response and that have a known MoA. Such a 'guilt-by-association' approach requires accurate MoA information for the most similar CMap small molecules, something that is not necessarily easy to find. In our case study, the target profiles for the neighboring compounds used in the MANTRA analysis were obtained using multiple means: we applied the KIBA method [38] to curated ChEMBL bioactivity data; we also performed manual literature searches and combined bioactivity data from several drug-target databases, including DrugBank, DUD, and ZINC (Tables 1 and 2 ). This drives the search for a pinosylvin MoA hypothesis towards fundamental MoA. We begin by looking individually at the closest neighbors of pinosylvin, and then continue to look at the closest neighbors as a group. We end this section by describing a novel insight into the information that can be gained about groups of compounds. 
Production of pinosylvin gene expression response profiles
We aimed to discover the unknown MoA of pinosylvin via the comparison of its transcriptional response profile to those of compounds in CMap of known MoA. The CMap data resource comprises genome-wide transcriptional response profiles of 1309 small molecules in human cell lines, mainly the prostate cancer cell line PC3 and the breast cancer cell line MCF7. Given that pinosylvin is not one of the small molecules present in CMap, in this analysis, gene expression response profiles of pinosylvin at different concentrations on PC3 and MCF7 cell lines were produced as input into the MANTRA and GFA methods to gain further insights into the molecular mechanisms behind the effects of pinosylvin. The MCF7 cell line is the main cell line used in the CMap data, but we also wanted to include the lesser-used PC3 cell line to enable assessment of prostate cancer-specific action and to facilitate analysis of noncontext-specific action by combining the results over the two cell lines (Fig. I) .
Given that the optimal concentration is not known for many compounds, most of the CMap compounds were applied to cell lines at a concentration of 10 mM. A subset of compounds was also applied at concentrations reported to be effective in cell culture or to approximate the maximum attainable plasma concentrations after therapeutic dosing, while another subset was profiled at a range of concentrations to explore the sensitivity of results to dose. To retain similarity in the methodology, we used a concentration of 10 mM for pinosylvin. We also produced expression data for the dose of 40 mM because previous studies have shown this to be a physiologically relevant, therapeutically effective, and nontoxic dose. The choice of dose for the other 1309 CMap compounds could affect the gene expression profiles and, thus, also the results produced from their comparison. Four batches of the three doses (0 mM, 10 mM, and 40 mM) were produced for each cell line, yielding a total of 24 samples. Unlike in the CMap data, which was produced over a period of 1 year, here the batches for each cell line were produced and RNA extracted simultaneously under the same conditions and, therefore, batch effect was not deemed to be an issue. Following the application of pinosylvin to the cell lines and RNA extraction for each dose-cell line pair, the Limma statistical package in R was used to assess differential expression with respect to the untreated hybridization. The probe-set identifiers were then ranked by the modified t-statistic.
The selected panel of differentially expressed probe set identifiers in each dose-cell line pair are called 'gene expression signatures' . The two gene expression profiles at dose 10 mM for MCF7 and PC3 had few probe sets with significant differential expression and, hence, were disregarded. Thus, in the analysis, we proceeded with the two gene expression profiles at a 40 mM dose, one for each cell line ( Fig. I) . 
Pinosylvin

FIGURE I
Pinosylvin was applied to a specific cancer cell line, here PC3, to elicit a transcriptional response profile that forms the input into the computational methods.
Closest neighbor approach
The simple idea behind looking at the drugs with the closest transcriptional response to pinosylvin is that two drugs with a similar MoA [by this we mean having cellular target(s) in common that contribute to the treatment response] will produce similar transcriptional changes. Out of all 1309 small molecules in the CMap data set, Chembridge 5707885 had the most similar transcriptional response to pinosylvin, as measured by the MANTRA method (Table 2 ). However, little is known about this compound apart from it having a transcriptional response similar to the natural phenol gossypol, which also occurs in the pinosylvin list, at position ten. Gossypol has been shown to have anticancer effects via various mechanisms [39, 40] , but it is difficult to pinpoint potential targets for pinosylvin from this association because gossypol is known to act on a widerange of targets, as discussed later. Hence, we move on, and consider the second closest neighbor, trifluoperazine. Trifluoperazine, a dopamine receptor D 2 (DRD2) antagonist, is an antipsychotic drug of the phenothiazine group. It is also an antagonist of serotonin type 2 receptors 5-HT 2A and 5-HT 2C , and a calmodulin (CaM) inhibitor ( Table 2 ). There is also evidence of trifluoperazine inhibiting tumor growth [41, 42] . This led us to question whether pinosylvin is a G-protein-coupled receptor (GPCR) ligand or a CaM inhibitor and, in particular, whether some of its anticancer effects might come via these mechanisms. There have been numerous links between GPCR ligands and anticancer activity [43] and CaM has an established role in cancer, both through apoptosis and invasion [44] . However, to our knowledge, the question of whether natural stilbenoids, such as pinosylvin, have an effect on prostate cancer via a GPCR-related mechanism has not been posed previously.
First, we tested pinosylvin against a set of 46 standard GPCRs. Although exceptionally high binding values were not obtained for any single target, ligand competition did seem selective to 5-HT 2 receptors. Building on the previous finding that 5-HT 2B receptors are expressed in PC3 cells, and that a 5-HT2B antagonist, SB-21550, inhibits PC3 cell proliferation [45] , we further tested pinosylvin together with the known 5-HT 2B agonist BW723C86 in cell viability and cell toxicity assays. However, BW723C86 did not abolish the antiproliferative activity of pinosylvin in PC3 cells, which suggests that the effect of pinosylvin is not mediated by 5-HT 2B receptors. So, for now, we put a GPCR-related mechanism out of the picture for pinosylvin, but we return to this line of enquiry later.
Second, we tested CaM inhibition using an invasion assay. Given that pinosylvin and our model compound trifluoperazine (a CaM inhibitor) had no effect on PC3 cell invasion, it is inconclusive whether pinosylvin inhibits CaM. However, our modelbased investigation did lead to the interesting side result that CaM inhibition is not key to invasion in PC3 cells.
Looking further down the list of compounds having a similar transcriptional response to that produced by pinosylvin, we find compounds that produce a range of transcriptional and posttranscriptional modifications ( Table 2 ). For example, Cytochalasin B affects the actin cytoskeleton [46] and so might induce broad transcriptional changes. Gossypol induces changes in signal transduction mediators involved in multiple protein expression and activity, and interacts with cellular and mitochondrial membranes [47] . Taken together with the fact that pinosylvin is low in the lists of closest neighbors of trifluoperazine and celastrol (the natural product fifth in the list of closest neighbors to pinosylvin), we postulated that pinosylvin acts on multiple targets, specifically on a subset of targets of trifluoperazine and celastrol.
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The MANTRA method first produces a so-called single 'Prototype Ranked List' (PRL) of genes for each of the 1309 compounds in the CMap data set. In other words, the cell line-dose level gene expression profiles for a given compound are merged into a single profile for the compound using a rank-aggregation algorithm [81] . This ranked list aims to capture the consensus transcriptional response of a compound across doses and cell lines, and also to overcome batch-effect issues in the CMap data. To enable comparison, we also produced a PRL for pinosylvin; however, we were in a balanced situation whereby we had an equal number of compound treatments over the two cell lines and, hence, we could produce the merged ranked list simply by summing the rank positions for a given probe set and reranking, rather than using the more complicated merging algorithm. Given that we used the HG-U133 + PM array plate in our experiment, we reduced the 54 715 probe sets in our data to match the 22 283 probe sets in the CMap data produced on the Affymetrix GeneChipW HG-U133A array to enable further computational analysis. Once we had a PRL for pinosylvin to compare with the PRLs of all 1309 CMap compounds (Fig. II) , the comparison was done via a distance measure based on Gene Set Enrichment Analysis (GSEA) to output a list of closest neighbors to pinosylvin (i.e., a ranked list of those CMap drugs with the most similar merged gene expression profiles to that of pinosylvin). The idea was that compounds with similar transcriptional profiles might share MoA. Hence, the next step was to look at the MoA of the nearest neighbors to pinosylvin. The analysis was done using the MANTRA 2.0 tool, which is an easy-to-use web-based tool for applying the MANTRA method (Table 1 , main text). As expected, when the individual non-merged MCF7 and PC3 expression profiles for pinosylvin were input into the MANTRA tool, these lists were the most similar to the merged pinosylvin list out of all CMap PRLs. An additional output of MANTRA 2.0 is a visualization of a drug network, where drugs are nodes and are joined by an edge if the distance (a measure of the similarity in transcriptional response) between them is below a certain threshold (here, a distance score of less than 0.8). A 'community' is defined as a group of nodes densely interconnected with each other and with fewer connections to nodes outside the group. In total, 106 communities were identified using an affinity propagation algorithm [82] ; each community was coded with a numerical identifier and one of its nodes was identified as the 'exemplar' of the community (i.e., the drug whose effect best represents the effects of the other drugs in the community). The top 17 nearest neighbors of the polyphenols pinosylvin, resveratrol, and genistein were included in the network diagrams for visualization purposes and the network diagram was modified using Cytoscape [83] (Fig. II) .
Using pathway information about closest neighbors
The transcriptional response profiles for a pair of drugs might be similar, even if their targets are not the same but if the drugs target the same pathway upstream of the translational effects. With this in mind, we mapped the known targets of the top five neighbors of pinosylvin (Table 2 ) onto pathways using Pathway Commons (Table 1) , and found that all except trifluoperazine point to an inhibition of nuclear factor kappa B (NF-kB) downstream of the epidermal growth factor receptor (EGFR) (Fig. 1) . This led to the hypothesis that the transcriptional profiles of these four drugs are similar to that of pinosylvin because of the ultimate inhibition of NF-kB. Subsequently, we found evidence to support our data-derived hypothesis: Lee et al. [48] showed that pinosylvin suppressed the production of proinflammatory mediators through the inhibition of the NF-kB pathway, a finding corroborated by Laavola et al. [49] . It is possible that this inhibition of NF-kB by pinosylvin is responsible for the proapoptotic effect seen in PC-3M-luc2 cells [21] , as is the case for the polyphenol curcumin through blocking phosphorylation of IkBa [50] .
Although NF-kB is involved in many processes and several signaling pathways, the example serves to highlight the idea of using pathway information from all of the closely related compounds to obtain novel MoA hypotheses. Extra support for the NF-kB hypothesis comes from the observation that celastrol (the fifth most similar drug to pinosylvin in terms of transcriptional response) is a potent antioxidant and anti-inflammatory drug [51] that has also been reported to have anticancer properties [52, 53] and to inhibit NF-kB activation through IKKb inhibition [54] .
Insights for groups of compounds
So far, we have used the MANTRA method to predict the MoA for pinosylvin. However, we end this section with a description of how the method also has potential to add insights into a group of compounds of the researcher's choice. Resveratrol (trans-3,5,4 0trihydroxystilbene) is a much-researched metabolite of pinosylvin, with a similar structure and many reported health benefits and anticancer properties [55] [56] [57] . Although it is not necessarily the case that two structurally similar compounds work in a similar way, as can be exemplified by the two structurally similar flavones apigenin and naringenin [58] , it would be interesting to investigate whether this is true for pinosylvin and resveratrol. By contrast, genistein (4 0 ,5,7-trihydroxyisoflavone) is a much-researched natural polyphenol that is structurally different to pinosylvin, and is not normally thought of as having similar mechanisms to the stilbenes. However, genistein is in Phase II clinical trials for prostate cancer (ClinicalTrials.gov Identifier: NCT01126879). Therefore, it is interesting to investigate how similar or different the lesser-researched polyphenol pinosylvin is to these muchresearched polyphenols, resveratrol and genistein. To investigate similarities between pinosylvin, resveratrol, and genistein, we mapped their closest compounds onto a network diagram, where links between compounds correspond to significant similarities in transcriptional response according to MANTRA (Box 2). First, the network approach used here highlighted unexpected similarities between pinosylvin and genistein. In particular, the transcriptional response that was most similar to that of genistein, was that of pinosylvin out of all 1309 CMap compounds, suggesting that a certain mode of action of pinosylvin is also common to genistein. Second, celastrol has links to pinosylvin and also to resveratrol and genistein. However, pinosylvin, resveratrol, and genistein are not among the top neighbors of celastrol. This suggests that a certain aspect of celastrol is common to each of these compounds. This aspect could be inhibition of NF-kB, because celastrol, resveratrol, and genistein are all known to inhibit NF-kB [54, 59] . It is not unexpected that pinosylvin, genistein, and resveratrol should have links to celastrol, given that Drug Discovery Today Volume 21, Number 7 July 2016 REVIEWS Celastrol 0.571 Inhibition of NF-kB activation through IKKb inhibition [54] More information on the many targets of celastrol [94] a Here we list the known targets of the drugs and the sources of this target information. The full list of closest compounds to pinosylvin in terms of transcriptional response, as produced by the MANTRA method, can be found in Table S1 in the supplemental information online. Pathway diagram showing relations between the cellular targets of four of the closest neighbors of pinosylvin. We mapped the known targets of the five most similar compounds in terms of their transcriptional response onto pathway diagrams using Pathway Commons (with Chembridge 5707885 replaced by the most similar drug having known targets, namely gossypol). This mapping led to the hypothesis that the transcriptional profiles of four of these five drugs, namely gossypol, tyrphostin AG-1478, cytochalasin B, and celastrol, are similar to that of pinosylvin because of the ultimate inhibition of nuclear factor kappa B (NF-kB). The target abbreviations are explained in Table 2 (main text).
natural polyphenols are known to have anti-inflammatory properties. To highlight differences between compounds in a group, one can compare the lists of closest neighbors for each compound. For example, despite their structural similarity, resveratrol is not the most similar compound to pinosylvin in terms of transcriptional response; resveratrol is number 46 in the ordered list of compounds that are similar to pinosylvin. Therefore, we hypothesized that these two compounds work differently in some fundamental way. By looking at the drugs that are solely in the list of closest compounds to resveratrol ( Table S2 in the supplemental information online), but not in the list for pinosylvin ( Table S1 in the supplemental information online), we can search for clues as to potential differences between these two structurally similar compounds. For example, monobenzone occurs in the resveratrol list at position 21, but does not produce a transcriptional response similar to that of pinosylvin. Monobenzone, which is structurally similar to resveratrol, is a drug used to treat the loss of skin color (vitiligo). This hints that one difference between resveratrol and pinosylvin is connected to melanin synthesis or excretion [60] .
Operation of the GFA method
In contrast to MANTRA, the GFA method of Khan et al. [12] segregates the drugs and their responses into so-called 'components', which are cell line specific and group together drugs with similar transcriptional responses over a particular subset of genes that are learned in a data-driven fashion (Box 3). A compound can be linked to several components, making it possible to identify GFA method of Khan et al.
GFA [12, 95] is a recent computational approach, based on the well-established factor analysis scheme, that decomposes transcriptional data sets into 'components' (also known as factors), which in turn can be used to create hypotheses for underlying biological processes. The method uses the gene expression response of each cell line separately to identify both the cross-cancer consensus effects as well as cancerspecific responses. Each component represents a distinct response in the data, and can be interpreted as a set of drugs, activating or repressing a set of genes in one or more cell lines. Therefore, the method can identify multiple mechanisms of each drug, while extracting a representative set of genes for each. The GFA method uses the treatment versus control differential expression data directly into the modeling process. To this end, the raw gene expression data of CMap were preprocessed to obtain a log 2 FC differential response for both of the cell lines separately. Using the expression data of the most abundant platform in CMap, HG-U133A, a total of 1154 drugs were found in both MCF7 and PC3 cell lines. Multiple concentrations of the drugs were combined to obtain a single reliable profile for each drug [84] . The gene expression of pinosylvin was processed analogously to obtain the treatment versus control differential gene expression response. With a threshold of jlog 2 FCj > 0.5, 164 genes were identified as expressed in either MCF7 or PC3 by pinosylvin treatment. GFA was then run on the two matrices of responses, MCF7 and PC3; each comprising 1155 drugs (including pinosylvin) and 164 genes. The analysis was done using the publically available R code of GFA (Table 1, TIPARP  ISG20  MYBL1  NAV2  IRS2  PGR  MYC  TMPRSS3  BCL2L11  ALDH1A3  TNS3  RWDD2A  ANKRA2  EGLN3 
FIGURE III
Group Factor Analysis (GFA) decomposed the two gene expression response data sets spanning the common 1155 drugs into separate components. multiple context-dependent MoAs for a compound. Moreover, because responses of drugs can be unique in various cancer types, GFA makes it possible to automatically identify which responses are common between cancers and which are specific to any one of the subtypes. The cell-specific responses might remain elusive when cell lines are merged, as is the standard choice in MANTRA. GFA also has the potential to use structural descriptors of compounds, such as 3D Pentacle descriptors, to identify the chemical properties linked to the responses. However, because there were structurally similar compounds to pinosylvin in the CMap data (e.g., resveratrol), we did not want the structural effects to dominate the findings and so did not include any structural descriptors in our analysis.
Key GFA components
The GFA model identified 30 components from the CMap data combined with the pinosylvin expression profiles. Seventeen of these components were shared between MCF7 and PC3 cell lines, and 13 captured responses specific to either of the cancer types. Each of these components was characterized by a set of drugs that SERPINI1  WDR19  RUNDC3B  DNAJC12  GLRX  ARMCX2  SLC26A2  EAF2  WIPI1  TRIB3  TIPARP  ID2  HSPA6  RWDD2A  ARMCX1  NUPR1  HSPA6  FZD4  CTGF  SERPINI1  WDR19  ANGPTL4  BCL6  TRIM9  PLK2  MYBL1  ID2  NAV2  GEM  DNAJC12   FIGURE 2 Component 1 'histone deactylase (HDAC) component' produced by the Group Factor Analysis (GFA) method. The GFA method segregates drugs and their transcriptional responses into so-called 'components' , where each component is characterized by a set of drugs that regulate the expression of genes in a similar fashion, forming hypotheses on the common action mechanisms. Component 1 captured a response of pinosylvin common to both MCF7 and PC3 cell lines. This component is characterized by the three HDAC inhibitors, scriptaid, vorinostat, and trichostatin A, thereby predicting a HDAC response for pinosylvin. Red indicates genes that are upregulated and blue genes that are downregulated.
regulate the expression of genes in a similar fashion, potentially forming hypotheses on the common action mechanisms. Two components were relevant to pinosylvin, labeled as components 1 and 2, while the remaining components captured responses of other drugs. Component 1 (Fig. 2 ) captured a response common on both MCF7 and PC3. This is a histone deacetylase (HDAC) inhibitor component characterized by the three HDAC inhibitors, scriptaid, vorinostat, and trichostatin A. Both pinosylvin and resveratrol are present in this component and, hence, as well as predicting a HDAC response for pinosylvin, such a role is also suggested for resveratrol (for which there is some prior evidence [61] ). There is some evidence that HDAC inhibitors can reprogram the NF-kB response in cancer cells [62] , linking this prediction with the NF-kB prediction above.
Component 2 (Box 3, Fig. III) captured the MCF7-specific response of pinosylvin and related drugs. The top drug in this component is colforsin, a water-soluble derivative of forskolin, which increases levels of cAMP. Cyclic AMP is an important signaling molecule in the regulation of prostate cancer [63] and breast cancer [64] cell proliferation. This led us to hypothesize that pinosylvin increases levels of cAMP. Interestingly, previous studies have shown that the structurally similar resveratrol increases the amount of cAMP by directly inhibiting cAMP-specific phosphodiesterases [65] (including PDE4, which is one of the most abundant cAMP-selective PDEs in PC3 cells [66] and also present in MCF7 [67] ). Furthermore, Liu et al. [68] showed that genistein increases cAMP in insulin-secreting INS-1 cells, possibly primarily via enhanced adenylate cyclase activity.
Given that there were also numerous steroidal compounds in component 2, we hypothesized that pinosylvin also works in a manner similar to steroids. As regards steroid receptors, nuclear estrogen receptors (ERa and ERb) are of particular interest, because they are known to interact with a range of steroidal and nonsteroidal compounds. However, if interaction with estrogen receptors was the common factor in component 2, then one would expect genistein to also be present in this component, because it is known to be an ERa agonist in MCF7 cells [69] . We continue this line of enquiry in the next section by taking into account the output also from the MANTRA method.
Taken together, the putative targets identified for pinosylvin (HDACs, GPCRs, and cAMP) are well in line with earlier data on the biological activities of pinosylvin, such as inhibition of cancer cell proliferation, induction of apoptosis, sensitization to TRAIL, and anti-inflammatory activities [21, 49, 70] . Further mechanistic studies are needed to confirm the relevance of these signaling molecules in mediating the anticarcinogenic and/or anti-inflammatory effects of pinosylvin. However, as regards to the putative steroid-like properties, our recent data indicate that pinosylvin, unlike genistein, does not target the classical nuclear steroid receptors ERa and the androgen receptor (AR) (L. Polari, PhD thesis, University of Turku, 2015, http://urn.fi/URN:ISBN:978-951-29-6101-6). Therefore, future studies focusing on the other steroid-related processes, such as steroid biosynthesis, or nongenomic steroid signaling, are warranted.
Combining information from both methods leads to novel insights
Combining the GPCR hypothesis for pinosylvin obtained from the MANTRA method with the above observations on steroidal compounds in component 2 obtained from the GFA method, led us to question whether the common factor in component 2 could be the G-protein-coupled estrogen receptor (GPER), also known as GPR30, and to ask whether pinosylvin binds to GPER. Furthermore, might the antiproliferative and proapoptotic effects seen in prostate cancer occur via this mechanism? This would fit with the prediction, discussed in the previous section, that pinosylvin increases cAMP, because GPER agonists have been shown to increase cAMP production [71] . In addition, GPER belongs to the same GPCR family as 5HT-2, which was highlighted as a potential target by the MANTRA method. It is also known that GPER is expressed both in MCF7 [72] and PC3 cells [73] .
GPER is a challenging target to validate, because there are no specific markers for GPER-mediated signaling. Furthermore, GPER ligand-binding studies are far from straightforward [71] . However, there is evidence that GPER is a relevant target in cancers, in particular for breast cancer and castration-resistant prostate cancer. GPER is expressed in clinical breast and prostate cancer specimens, and the GPER-selective agonist G1 modulates the growth of breast and prostate cancer cells in vitro and in vivo xenografts [71, 73, 74] . The polyphenols genistein and resveratrol have both been shown to have a GPER-related mechanism, genistein in certain cancer cell lines, [71] and, therefore, one can also hypothesize such a role for pinosylvin. However, a multitude of MoAs has been proposed for these two well-researched polyphenols [75, 76] , and it is not clear a priori which of them apply to pinosylvin.
The current data-driven exploration highlighted GPER as a potential target for pinosylvin, and the existing studies provided supporting published evidence for this novel hypothesis in the contexts of both prostate and breast cancer. In conclusion, by combining the hypotheses from the two computational models, we developed a hypothesis that would not have been obtained from either method alone.
Concluding remarks and future directions
The elucidation of compound MoA is a key part of the drug discovery process. We have provided an overview of the common concepts in the computational network pharmacology methods, which use transcriptional response profiles to provide hypotheses for the MoA of compounds. The specific case study described here highlights how the data-driven approaches can provide researchers with completely unintuitive hypotheses for MoA, thus potentiating novel findings, once carefully validated using in vitro or in vivo assays. In addition, our case study adds to evidence that the network-based methods are particularly useful for natural products, which typically are multitargeted [20] . However, as demonstrated over the course of the application case study, experimental validation of the model predictions can be far from trivial, and establishing the MoA of a compound might require several iterations of the computational and experimental phases.
Using the MANTRA and GFA methods, we developed hypotheses for the MoA of the less-researched natural polyphenol pinosylvin. In particular, the MANTRA method predicted a GPCR-related mechanism and CaM inhibition, although this remained inconclusive following our initial experiments, and inhibition of NF-kB, for which we found literature evidence. The MANTRA method also hinted at commonalities between pinosylvin and genistein, which are stronger than those between pinosylvin and a structurally more similar polyphenol, resveratrol. Using the GFA method, a HDAC response was predicted for pinosylvin, as well as an increase in levels of cAMP and steroid-like activity. By combining the information from these two computational methods, we were able to predict a GPER-mediated role for pinosylvin in prostate cancer. The question of whether natural stilbenoids have an effect on prostate cancer via a GPCR-related mechanism has not been posed previously, underscoring the potential of such unbiased approaches to suggest novel hypotheses.
In the future, computational network pharmacology methods will benefit from new phenotypic response data, for example that being produced by the Library of Integrated Network-based Cellular Signatures project (LINCS, http://www.lincsproject.org/), as well as high-quality, context-specific gene regulatory networks and more reliable drug-target and pathway information. Although novel computational methods are simultaneously being created, it is useful to also consider novel applications and combinations of existing methods and their extensions, as highlighted through the current work. For example, Iorio et al. [77] recently extended the MANTRA computational pipeline to filter out the effect of transcriptional changes resulting from nonspecific secondary MoA. In particular, they used an iterative, network-guided, semisupervised approach to refine the gene expression signature of the compound of interest to produce a transcriptional signature representative of the primary MoA. They showed how the approach can be used to disentangle the indirect mitotic arrest and general microtubule disruption effects of paclitaxel from its primary microtubule stabilization effect, and further used the method to find novel microtubule stabilizers [77] .
MANTRA and GFA are both designed to identify similarities between drugs based on their large-scale phenotypic response profiles. Further advances in computational approaches might benefit cases where the goal is to illuminate differences between two drugs. For instance, a possible future direction would be to explore how these methods can be extended for optimally identifying differences between response mechanisms of two candidate drugs. Furthermore, future efforts to consider multiple levels of MoA for the neighboring compounds in the MANTRA method, beyond direct target effects to also include indirect and downstream signaling effects, might yield a wider understanding of the various drug response pathways. Finally, the GFA method learns the response similarities in an entirely data-driven fashion. Supplementing the data-driven nature with prior information of known pathway interactions and biochemical processes might prove useful for prediction of action mechanisms.
The concept of network pharmacology not only considers single multitargeted drugs to be of potential use to treat complex diseases, but also combinations of compounds, the rationale being that a combination of drugs might target nodes on compensatory pathways, countering problems such as emerging drug resistance. We did not touch on approaches for predicting effective drug combinations here, but computational methods that can prioritize the most therapeutically effective combinations of compounds for experimental validation are important because of the impracticality of testing all possible drug combinations, given that the number of combinations increases exponentially with the number of drugs to be screened. These methods are reviewed elsewhere (e.g., [78, 79] ).
We hope that, through this detective story into the MoA of pinosylvin, we have furnished researchers new to computational network pharmacology methods with the background to carry out similar studies for their own compounds of interest, while providing more experienced researchers in the field with novel insights into how the methods can be applied and their results experimentally validated.
